Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration

Abstract

Disorders of the skin or mucous membranes which are linked to migration of Langerhans cells are treated by the administration of an effective amount of at least one retinoid, optionally in combination with a PKC inhibitor.

1 .- 11 . (canceled) 
     
     
         12 . A method for the treatment of disorders of the skin or mucous membranes linked to Langerhans cell migration comprising the administration, to a person in need thereof, of an effective amount of a composition comprising at least one retinoid. 
     
     
         13 . The method of  claim 12 , wherein said disorder is selected from the group consisting of allergic reactions, atopic eczema, contact eczema, skin sensibility, skin reactivity, inflammatory dermatoses, irritant dermatitis, transplant rejection, autoimmune diseases, inflammatory diseases, psoriasis and photoimmunosuppression. 
     
     
         14 . The method of  claim 12 , wherein said retinoid is selected from the group consisting of nonaromatic retinoids, vitamin A, monoaromatic retinoids and polyaromatic retinoids. 
     
     
         15 . The method of  claim 14 , wherein said nonaromatic retinoid is selected from the group consisting of retinaldehyde, tretinoin and 9-cis-retinoic acid. 
     
     
         16 . The method of  claim 14 , wherein said monoaromatic retinoid is selected from the group consisting of etretinade, all-trans-acitretin and motrerinide. 
     
     
         17 . The method of  claim 14 , wherein said polyaromatic retinoid is selected from the group consisting of adapalene, tazarotene, tamibarotere and arotinoid methyl sulfone. 
     
     
         18 . The method of  claim 12 , wherein the composition further comprises a PKC-inhibitor selected from the group consisting of peptide extracts of lupin, sphingolipids and ceramids. 
     
     
         19 . The method of  claim 18 , wherein the sphingolipid is selected from the group consisting of sphingosine, phytosphingosine and isomers thereof. 
     
     
         20 . The method of  claim 18 , wherein the peptide extract of lupin is LU105. 
     
     
         21 . The method of  claim 12 , wherein the retinoid concentration in the composition is between approximately 0.001 and approximately 10% by weight, relative to the total weight of the composition. 
     
     
         22 . A method for the treatment of disorders of the skin or mucous membranes linked to Langerhans cell migration comprising the administration, to a person in need thereof of an effective amount of a composition comprising at least one retinoid selected from the group consisting of vitamin A and 9-cis-retinoic acid. 
     
     
         23 . The method of  claim 22 , wherein the composition further comprises a PKC-inhibitor selected from the group consisting of peptide extracts of lupin, sphingolipids and ceramids.